FTC Rebukes Supernus Efforts To Block Sales Of Injector Pen For Use With Generic Apokyn
Executive Summary
Agency refutes Supernus’ defense that Sage’s generic drug cartridges are ‘free-riding’ on the supply of the injector pen for its branded product. Company’s alleged exclusionary contract with pen distributor and pressure on specialty pharmacies not to provide the generic involve important antitrust issues, FTC tells court.
You may also be interested in...
Teva Targeted Over Alleged US Nuvigil-EpiPen Conspiracy
Teva secretly conspired with Mylan and Pfizer to delay generic versions of one another’s lucrative brands by several years, a newly-filed US antitrust lawsuit naming the Israeli firm alleges.
Delisting Of Jazz’s Xyrem Patent In Orange Book Could Spur More Infringement Counterclaims
Jazz’s REMS patent on distribution of Xyrem does not belong in the Orange Book because it is directed to systems rather than a method of using the drug, court rules, agreeing with FTC’s analysis.
FTC Steps Into FDA’s ‘Ministerial’ Gap, Seeks Delisting Of REMS Patent
Jazz’s REMS patent appears to cover only a method of distributing Xyrem not a method of using the drug and if so should be delisted from FDA’s Orange Book, FTC argues in Jazz infringement suit against Avadel, which had itself sued FDA seeking release from patent certification requirement.